BioSpace News Archive

Tempus, a leader in artificial intelligence and precision medicine, today announced a strategic collaboration to develop a companion diagnostic (CDx) test with A2 Biotherapeutics for its new therapy targeting patients with Loss of Heterozygosity (LOH). It is anticipated that this collaboration could also provide a platform for the development of further CDx tests for A2’s other clinical development programs

Progenity, Inc., a biotechnology company with an established track record of success in developing and commercializing molecular testing products, provided 2021 full-year financial guidance.

CONMED Corporation (NYSE: CNMD) today announced that it will report financial results for the fourth quarter and full year 2020 after the market close on Wednesday, January 27, 2021

BridgeBio Pharma, Inc. (“BridgeBio”) (Nasdaq: BBIO) and Eidos Therapeutics, Inc. (“Eidos”) (Nasdaq: EIDX) announced today that the acquisition of shares of common stock of Eidos not held by BridgeBio or its subsidiaries, on the terms and subject to the conditions of their previously announced merger agreement, is expected to close on or about January 26, 2021.

Masimo Corporation (Nasdaq: MASI) today announced select preliminary financial and operational results for the full-year ended January 2, 2021 and provided estimates for its full-year 2021 financial guidance.

PTC Therapeutics, Inc. announced that on January 6, 2021 it approved non-statutory stock options to purchase an aggregate of 13,465 shares of its common stock and 4,665 restricted stock units, each representing the right to receive one share of its common stock upon vesting, to 10 new employees.

Prominent Orange County Physician Group Serving Thousands of Patients with Cancer and Blood Diseases Chooses to Join MemorialCare Medical Group, Expand Access to Local Medical Services

This is the first commercial pharmaceutical agreement Aker BioMarine is entering for its new LYSOVETA business area.

Evoke Pharma, Inc. (Nasdaq: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, today announced that it has priced an underwritten public offering of 5,000,000 shares of its common stock at a price to the public of $2.50 per share

Spine Industry Leader Brings Decades of Experience Introducing New Products Designed to Improve Patient Care